Related Experiment Video
Updated: May 21, 2025

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Published on: February 10, 2023
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress
Jay R Anand1, Gaith N Droby2, Sayali Joseph1
1Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Abstract:
Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA damage response (DDR) mechanisms for cell survival. Different oncogenic stimuli signal via distinct mechanisms in every cancer setting. The DDR is also pathologically reprogrammed and deployed in diverse ways in different cancers. Because mutant KRAS is the driver oncogene in 90% of pancreatic ductal adenocarcinomas (PDACs), here we have investigated DDR mechanisms by which KRAS-induced DNA replication stress is tolerated in normal human pancreatic epithelial cells [human pancreatic nestin-expressing (HPNE) cells]. Using a candidate screening approach, we identify TRIP13 as a KRASG12V-induced messenger RNA that is also expressed at high levels in PDAC relative to normal tissues. Using genetic and pharmacological tools, we show that TRIP13 is necessary to sustain ongoing DNA synthesis and viability specifically in KRASG12V-expressing cells. TRIP13 promotes survival of KRASG12V-expressing HPNE cells in a homologous recombination (HR)-dependent manner. KRASG12V-expressing HPNE cells lacking TRIP13 acquire hallmark HR deficiency phenotypes, including sensitivity to inhibitors of translesion synthesis and poly-ADP ribose polymerase. Established PDAC cell lines are also sensitized to intrinsic DNA damage and therapy-induced genotoxicity following TRIP13 depletion. Taken together, our results expose TRIP13 as an attractive new and therapeutically tractable vulnerability of KRAS-mutant PDAC.
Insights
Oncogene activation causes DNA replication stress, requiring DNA damage response (DDR) for survival. We found TRIP13 is essential for KRAS-mutant pancreatic cancer cells, offering a new therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Oncogene activation in normal cells triggers DNA replication stress, creating a dependency on DNA damage response (DDR) pathways for survival.
- The DDR is pathologically altered in various cancers, with distinct oncogenic stimuli employing unique signaling mechanisms.
- Mutant KRAS drives 90% of pancreatic ductal adenocarcinomas (PDACs), highlighting the need to understand KRAS-induced DDR in this cancer.
Purpose of the Study:
- To investigate the DDR mechanisms that enable tolerance of KRAS-induced DNA replication stress in normal human pancreatic epithelial cells (HPNE cells).
- To identify novel DDR players involved in KRAS-driven pancreatic cancer.
- To explore TRIP13 as a potential therapeutic vulnerability in KRAS-mutant PDAC.
Main Methods:
- Candidate screening approach to identify KRAS-induced genes.
- Genetic and pharmacological tools to assess TRIP13 function in KRASG12V-expressing HPNE cells.
- Evaluation of homologous recombination (HR) dependency and sensitivity to genotoxic agents and inhibitors in TRIP13-depleted cells and PDAC cell lines.
Main Results:
- TRIP13 mRNA is upregulated by KRASG12V and highly expressed in PDAC compared to normal tissues.
- TRIP13 is essential for DNA synthesis and viability in KRASG12V-expressing cells.
- TRIP13 depletion in KRASG12V-expressing cells leads to HR deficiency phenotypes and sensitivity to translesion synthesis and PARP inhibitors.
- TRIP13 depletion sensitizes established PDAC cell lines to DNA damage and genotoxic therapies.
Conclusions:
- TRIP13 is a KRASG12V-induced gene crucial for maintaining DNA synthesis and survival in KRAS-mutant pancreatic cells.
- TRIP13 functions in a homologous recombination-dependent manner, and its depletion confers sensitivity to HR deficiency-associated liabilities.
- TRIP13 represents a novel and therapeutically actionable vulnerability in KRAS-mutant pancreatic ductal adenocarcinoma.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Abnormal Proliferation
Restarting Stalled Replication Forks
The Intrinsic Apoptotic Pathway
The DNA Replication Fork

